Recent Publications

Recent publications on Mucosis’ technology and vaccine programs are listed below.

Detection and Localization of Single LysM-Peptidoglycan Interactions G. Andre, K. Leenhouts, P. Hols, and Y. F. Dufrêne. J. Bacteriol. 190 (2008):7079–7086

Development of lactococcal GEM-based pneumococcal vaccines. S.A.L. Audouy, S. van Selm, M.L. van Roosmalen, E. Post, R. Kanninga, J. Neef, S. Estevão, E.E.S. Nieuwenhuis, P.V. Adrian, K. Leenhouts, P.W.M. Hermans. Vaccine 25 (2007):2497–2506.

Lactococcus lactis GEM particles displaying pneumococcalantigens induce local and systemic immune responses following intranasal immunization. S.A.L. Audouy, M.L. van Roosmalen, J. Neef, R. Kanninga, M. van Deemter, S. van Selm, G.T. Robillard, K.J. Leenhouts, P.W.M. Hermans. Vaccine 24 (2006):5434-5441.

Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. R. Ramasamy, S. Yasawardena, A. Zomer, G. Venema, J. Kok, K. Leenhouts. Vaccine 24 (2006):3900-3908

Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. M.L. van Roosmalen, R. Kanninga, M. El Khattabi, J. Neef, S. Audouy, T. Bosma, A. Kuipers, E. Post, A. Steen, J. Kok, G. Buist, O.P. Kuipers, G. Robillard, K. Leenhouts. Methods 38 (2006):144-149.

A novel surface display system for proteins on non-genetically modified Gram-positive bacteria. T. Bosma, R. Kanninga, J. Neef, S.A.L. Audouy, M.L. van Roosmalen, A. Steen, G. Buist, J. Kok, O.P. Kuipers, G. Robillard, K. Leenhouts. Appl. Environ. Microbiol. 72 (2006):880-889.

Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents. Steen, A., G. Buist, K. J. Leenhouts, M. El Khattabi, F. Grijpstra, A. L. Zomer, G. Venema, O. P. Kuipers, and J. Kok. J. Biol. Chem. 278 (2003):23874-23881.

31.05.10 Mucosis receives financial support from the Dutch government for its FluGEM program
more >

27.04.10 Mucosis appoints Dr. Roberto Grimandi as chief medical officer
more >

22.09.09 Mucosis receives key US patent covering its Mimopath™ technology
more >

28.01.09 Mucosis B.V. and PATH start development of pneumococcal vaccines
more >

15.12.08 Mucosis B.V. and TNO announce flu vaccine research and development partnership.
more >

10.12.07 News article in “Het Financieele Dagblad”.
more >

06.11.08 Mucosis B.V. appoints Dr. Govert Schouten as CEO. more >

10.09.07 Mucosis raises € 3 million in first financing round more >